Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sonoma Pharmaceuticals (SNOA)
NASDAQ:SNOA
RESEARCH TOOLSreports
Sonoma Pharmaceuticals (SNOA) Stock Price & Analysis
204 Followers
SNOA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.12 - $1.52
Previous Close$0.17
Volume3.32M
Average Volume (3M)1.96M
Market Cap
$2.58M
Enterprise Value$555.79K
Total Cash (Recent Filing)$2.41M
Total Debt (Recent Filing)$385.00K
Price to Earnings (P/E)-0.2
Beta1.69
Next Earnings
Jul 10, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding15,607,433
10 Day Avg. Volume801,597
30 Day Avg. Volume1,962,229
Standard Deviation0.23
R-Squared0.09
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.37
Price to Sales (P/S)0.19
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.05
Enterprise Value/Gross Profit0.12
Enterprise Value/Ebitda-0.11
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Sonoma Pharmaceuticals News
PremiumCompany Announcements
Sonoma Pharmaceuticals Presents Business and Financial Update
PremiumCompany Announcements
Sonoma Pharmaceuticals Outlines Growth and Challenges
Ownership Overview
23.87% Insiders
0.25% Mutual Funds
0.02% Other Institutional Investors
75.85% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SNOA FAQ
What was Sonoma Pharmaceuticals’s price range in the past 12 months?
Sonoma Pharmaceuticals lowest stock price was $0.12 and its highest was $1.52 in the past 12 months.
What is Sonoma Pharmaceuticals’s market cap?
Currently, no data Available
When is Sonoma Pharmaceuticals’s upcoming earnings report date?
Sonoma Pharmaceuticals’s upcoming earnings report date is Jul 10, 2024 which is in 81 days.
How were Sonoma Pharmaceuticals’s earnings last quarter?
Sonoma Pharmaceuticals released its earnings results on Feb 08, 2024. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.208 by $0.148.
Is Sonoma Pharmaceuticals overvalued?
According to Wall Street analysts Sonoma Pharmaceuticals’s price is currently Overvalued.
Does Sonoma Pharmaceuticals pay dividends?
Sonoma Pharmaceuticals does not currently pay dividends.
What is Sonoma Pharmaceuticals’s EPS estimate?
Sonoma Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sonoma Pharmaceuticals have?
Sonoma Pharmaceuticals has 15,607,433 shares outstanding.
What happened to Sonoma Pharmaceuticals’s price movement after its last earnings report?
Sonoma Pharmaceuticals reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.208. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sonoma Pharmaceuticals?
Among the largest hedge funds holding Sonoma Pharmaceuticals’s share is Hussman Strategic Advisors Inc. It holds Sonoma Pharmaceuticals’s shares valued at N/A.
---
Sonoma Pharmaceuticals Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 3.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.48%
12-Months-Change
Fundamentals
Return on Equity
-82.87%
Trailing 12-Months
Asset Growth
4.95%
Trailing 12-Months
Company Description
Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc. engages in identifying, developing, and commercializing therapies for chronic skin conditions. The company offers solutions in dermatology, animal healthcare, and advanced tissue care product areas. Its products target skin diseases including acne, atopic dermatitis, scarring, infections, itch, pain, and harmful inflammatory responses. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Petaluma, CA.
---
SNOA Stock 12 Months Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering SNOA
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-83.00%
initiated a buy rating 8 months ago
Copying Jeffrey Cohen's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -83.00% per trade.
---